Brokerages Set GeneDx Holdings Corp. (NASDAQ:WGS) Price Target at $96.43

GeneDx Holdings Corp. (NASDAQ:WGS) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $96.4286.

Several analysts have issued reports on the stock. Jefferies Financial Group set a $150.00 price target on shares of GeneDx in a report on Monday, February 23rd. Wells Fargo & Company reissued an “overweight” rating and set a $75.00 price objective (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Zacks Research downgraded shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 24th. Guggenheim reduced their price objective on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Finally, Piper Sandler reissued an “overweight” rating and set a $130.00 price objective (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th.

Insider Activity at GeneDx

In other news, Director Casdin Capital, Llc acquired 185,000 shares of GeneDx stock in a transaction that occurred on Tuesday, May 19th. The shares were acquired at an average price of $42.60 per share, with a total value of $7,881,000.00. Following the completion of the purchase, the director owned 3,367,164 shares of the company’s stock, valued at approximately $143,441,186.40. This represents a 5.81% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Keith A. Meister acquired 533,758 shares of GeneDx stock in a transaction that occurred on Thursday, May 7th. The shares were purchased at an average cost of $37.86 per share, for a total transaction of $20,208,077.88. Following the purchase, the director directly owned 3,761,908 shares of the company’s stock, valued at approximately $142,425,836.88. This trade represents a 16.53% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 2,256,420 shares of company stock worth $93,144,340 and have sold 77,287 shares worth $5,153,215. Corporate insiders own 29.60% of the company’s stock.

Hedge Funds Weigh In On GeneDx

Several institutional investors and hedge funds have recently modified their holdings of WGS. Kestra Advisory Services LLC acquired a new position in GeneDx during the fourth quarter worth approximately $27,000. Jones Financial Companies Lllp increased its position in GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares during the last quarter. Ramirez Asset Management Inc. acquired a new position in GeneDx during the fourth quarter worth approximately $33,000. Greenline Wealth Management LLC acquired a new position in GeneDx during the fourth quarter worth approximately $33,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in GeneDx during the fourth quarter worth approximately $35,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Hedge fund manager Eli Casdin is reportedly adding to his GeneDx position, which may be seen as a sign that some sophisticated investors still view the stock as undervalued. Hedge Funder Eli Casdin Is Loading up on GeneDx Shares
• Neutral Sentiment: Several law firms continue to remind investors about the pending securities class action and the August 3 lead-plaintiff deadline. These notices keep the lawsuit in focus, but do not add new operational developments. Investor Alert: Pomerantz Law Firm Reminds Investors…
• Neutral Sentiment: Additional legal updates from Rosen, Faruqi & Faruqi, Schall, Robbins, and others reinforce the litigation backdrop tied to GeneDx’s Fabric Genomics acquisition and the Q1 2026 selloff. ROSEN, TOP RANKED INVESTOR COUNSEL…
• Negative Sentiment: GeneDx CEO Katherine Stueland and CFO Kevin Feeley both sold shares this week. The company says the sales were for tax withholding tied to vesting equity awards, but insider selling can still weigh on sentiment. CEO Form 4 Filing
• Negative Sentiment: The biggest overhang remains the securities class action alleging GeneDx misled investors about reimbursement rates, margin pressure, and the impact of the Fabric Genomics acquisition after a major stock drop and write-off tied to the deal. GeneDx Holdings (WGS) Faces Securities Class Action…

GeneDx Stock Down 1.8%

Shares of NASDAQ WGS opened at $59.92 on Monday. GeneDx has a 12-month low of $32.21 and a 12-month high of $170.87. The company has a market capitalization of $1.78 billion, a PE ratio of -22.36 and a beta of 1.96. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The firm’s 50-day moving average is $54.95 and its two-hundred day moving average is $90.19.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The business had revenue of $102.25 million during the quarter, compared to analysts’ expectations of $112.46 million. During the same period last year, the company earned ($0.23) EPS. Equities analysts anticipate that GeneDx will post -1 EPS for the current fiscal year.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.